Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARGX 
argenx NV ADR (ARGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ARGX (3-star) is a STRONG-BUY. BUY since 36 days. Simulated Profits (27.85%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $814.35
1 Year Target Price $814.35
| 14 | Strong Buy |
| 7 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.6% | Avg. Invested days 54 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 46.90B USD | Price to earnings Ratio 38.45 | 1Y Target Price 814.35 |
Price to earnings Ratio 38.45 | 1Y Target Price 814.35 | ||
Volume (30-day avg) 22 | Beta - | 52 Weeks Range 510.06 - 779.03 | Updated Date 09/15/2025 |
52 Weeks Range 510.06 - 779.03 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 19.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 41.03% | Operating Margin (TTM) 21.08% |
Management Effectiveness
Return on Assets (TTM) 4.83% | Return on Equity (TTM) 24.72% |
Valuation
Trailing PE 38.45 | Forward PE 30.58 | Enterprise Value 42389048192 | Price to Sales(TTM) 15.03 |
Enterprise Value 42389048192 | Price to Sales(TTM) 15.03 | ||
Enterprise Value to Revenue 13.88 | Enterprise Value to EBITDA 61.47 | Shares Outstanding 61199900 | Shares Floating 61146679 |
Shares Outstanding 61199900 | Shares Floating 61146679 | ||
Percent Insiders - | Percent Institutions 53.37 |
Upturn AI SWOT
argenx NV ADR
Company Overview
History and Background
argenx NV ADR was founded in 2008. It is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It has evolved from a research organization to a commercial stage company with a focus on differentiated antibody-based medicines.
Core Business Areas
- Immunology Solutions: Develops and commercializes a portfolio of differentiated antibody-based medicines for severe autoimmune diseases and cancer.
- Innovation Center: Utilizes its SIMPLE Antibody platform to develop novel therapeutic antibodies.
Leadership and Structure
argenx is led by CEO Tim Van Hauwermeiren. The company has a board of directors and a management team responsible for various functions, including R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- VYVGART (efgartigimod): A human IgG1 antibody fragment designed to reduce pathogenic IgG antibodies. It is approved for the treatment of generalized myasthenia gravis (gMG). Revenue generated by this product in 2023 was $1.2 billion. Competitors include other treatments for gMG such as Soliris (alecumab) from Alexion Pharmaceuticals (now part of AstraZeneca) (AZN), Ultomiris (ravulizumab) from Alexion, and immunosuppressants.
- VYVGART Hytrulo: The subcutaneous formulation of efgartigimod. Competitors are same as VYVGART.
Market Dynamics
Industry Overview
The immunology market is growing rapidly, driven by increasing prevalence of autoimmune diseases and advancements in therapeutic options. There is high demand for new and effective treatments.
Positioning
argenx is positioned as a leader in FcRn blockade technology with VYVGART. It has a first-mover advantage in the gMG market and a strong pipeline of potential new therapies.
Total Addressable Market (TAM)
The TAM for FcRn antagonists in autoimmune diseases is estimated to be in the billions of dollars. argenx is aiming to capture a significant share of this market with its broad pipeline of potential indications for efgartigimod.
Upturn SWOT Analysis
Strengths
- First-to-market FcRn antagonist
- Strong clinical data for VYVGART
- Broad pipeline of potential new indications
- Robust SIMPLE Antibody platform
- Experienced management team
Weaknesses
- Reliance on VYVGART for revenue
- Competition from established players
- High R&D expenses
- Dependence on regulatory approvals
- Relatively new commercial infrastructure
Opportunities
- Expanding VYVGART indications
- Developing new antibody-based therapies
- Partnering with other companies
- Geographic expansion
- Advancements in drug delivery technologies
Threats
- Competition from biosimilars
- Unfavorable regulatory decisions
- Clinical trial failures
- Economic downturn
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- AZN
- JNJ
- LLY
Competitive Landscape
argenx has a competitive advantage with its first-to-market FcRn antagonist. However, it faces competition from established pharmaceutical companies with existing therapies for autoimmune diseases.
Growth Trajectory and Initiatives
Historical Growth: argenx has experienced significant growth in recent years, driven by the clinical success and commercial launch of VYVGART.
Future Projections: Analysts project continued revenue growth for VYVGART as it gains market share in gMG and expands into new indications. Expansion into new markets should help boost the company revenue.
Recent Initiatives: argenx is focused on expanding the label for VYVGART, advancing its pipeline of novel antibodies, and strengthening its commercial infrastructure.
Summary
Argenx is a biotechnology company with a strong foundation in FcRn antagonist technology, as demonstrated by the success of VYVGART. The company needs to diversify revenue away from its dependence on VYVGART, and navigate the challenges of competition. Continued successful clinical trials and regulatory approvals will be essential for long-term growth. A strong cash position will help fund future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Company Press Release
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About argenx NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-05-18 | Co-Founder, CEO & Executive Director Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1599 | Website https://argenx.com |
Full time employees 1599 | Website https://argenx.com | ||
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.